行情

PSTV

PSTV

Plus Therapeutics Inc
NASDAQ

实时行情|Nasdaq Last Sale

1.500
-0.030
-1.96%
休市 16:00 11/26 EST
开盘
1.500
昨收
1.530
最高
1.520
最低
1.470
成交量
3.29万
成交额
--
52周最高
5.42
52周最低
1.420
市值
2,304.00万
市盈率(TTM)
-0.9832
分时
5日
1月
3月
1年
5年
Is Plus Therapeutics (NASDAQ:PSTV) A Risky Investment?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Simply Wall St. · 5天前
Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial
Benzinga · 11/18 19:18
Plus Therapeutics discloses interim data for Rhenium-186 NanoLiposome in glioblastoma
Announcing interim results from the first-in-human trial for its lead candidate Rhenium-186 NanoLiposome, Plus Therapeutics (NASDAQ:PSTV) said the drug was well tolerated with no dose-limiting toxicities in the study involving
Seekingalpha · 11/18 14:04
BRIEF-Plus Therapeutics Announces Positive Interim Data From ReSPECT™-GBM Phase 1 Clinical Trial
reuters.com · 11/18 13:35
Plus Therapeutics Highlights Presentation Of Data From ReSPECT-GBM Phase 1 Clinical Trial At 2021 Society For Neuro-Oncology Annual Meeting
Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving absorbed dose greater than 100 Gy is 453.8 days and
Benzinga · 11/18 13:04
Plus Therapeutics Announces Positive Interim Data from ReSPECT™-GBM Phase 1 Clinical Trial at the 2021 Society for Neuro-Oncology Annual Meeting
Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities Mean and median overall survival in patients receiving absorbed dose greater than 100 Gy is 453.8 days and 330 days, respectively, with seven pa...
GlobeNewswire · 11/18 13:00
Plus Therapeutics Announces New Employment Inducement Grants
AUSTIN, Texas, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company...
Globe Newswire · 11/12 12:30
Plus Therapeutics Receives FDA Fast Track Designation For 186RNL Targeted Radiotherapeutic For Leptomeningeal Metastases
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced
Benzinga · 11/09 12:04
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解PSTV最新的财务预测,通过PSTV每股收益,每股净资产,每股现金流等数据分析Plus Therapeutics Inc近期的经营情况,然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测PSTV价格均价为6.67,最高价位7.00,最低价为6.00。
最高7.00
均价6.67
最低6.00
现价1.500
EPS
实际EPS
预期EPS
-0.54-0.40-0.27-0.13
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 34
机构持股: 130.23万
持股比例: 8.48%
总股本: 1,536.00万
类型机构数股数
增持
4
13.11万
建仓
0
0
减持
6
28.92万
平仓
4
15.04万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+2.30%
制药与医学研究
+0.44%
高管信息
Non-Executive Chairman/Independent Director
Richard Hawkins
President/Chief Executive Officer/Director
Marc Hedrick
Chief Financial Officer
Andrew Sims
Other
Norman LaFrance
Independent Director
Howard Clowes
Independent Director
Robert Lenk
Independent Director
Greg Petersen
Independent Director
Annigje Van Es-johansson
暂无数据
PSTV 简况
Plus Therapeutics Inc是一家临床阶段的制药公司。该公司致力于为癌症患者开发治疗方法。该公司为了患者和医疗提供商的利益,提供纳米技术平台,以重新规划并改进其主力化疗药物。该公司致力于开发通用肿瘤药物,解决未满足的医疗需求和市场需求。该公司的主要候选产品DocePLUS是一种白蛋白稳定的多西紫杉醇PEG化脂质体制剂。DocePLUS是为治疗小细胞肺癌(SCLC)患者而开发的。该公司还在开发DoxoPLUS,这是一种通用的多柔比星PEG化脂质体制剂。DoxoPLUS是为治疗乳腺癌、卵巢癌、多发性骨髓瘤和卡波西肉瘤而开发的。该公司还专注于开发Rhenium-186 NanoLiposome(186RNL),用于治疗复发性胶质母细胞瘤,是一种罕见的、无法治愈的致命疾病。

微牛提供Plus Therapeutics Inc(NASDAQ-PSTV)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PSTV股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PSTV股票基本功能。